ClinicalTrials.gov
public full text
Public Domain
A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD
The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Attentin® in Children and Adolescents With ADHD - A Non-interventional Study#1095823
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD#892506
- Classroom Study of SPN-812 in Children With ADHD#869226
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD#969926
- Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD#836626
Record · ID 801830
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive